Roots Analysis is pleased to announce thepublication of its recent study, titled, “Biopharma Contract Manufacturing Market (3rdEdition), 2019-2030.”
The report features an extensive study on thecontract service providers within the biopharmaceutical industry. The studyfeatures in-depth analysis, highlighting the capabilities of a diverse set ofbiopharmaceutical CMOs and CDMOs. Amongst other elements, the report includes:
§ A detailed review of the overall landscape of thebiopharmaceutical contract manufacturing market, featuring a comprehensive listof active CMOs and detailed analysis of the manufacturing service providersbased on a number of parameters.
§ Elaborate profiles of key players that have a diverse rangeof capabilities for the development, manufacturing, and packaging of biologics.
§ A detailed discussionon the key enablers in this domain, including certain niche product classes,which are likely to have a significant impact on the growthof the contract services market.
§ A case study on thegrowing global biosimilars market, highlighting the opportunities forbiopharmaceutical CMOs and CDMOs.
§ A case studycomparing the key characteristics of large molecule and small molecule drugs,along with details on the various steps involved in their respectivemanufacturing processes.
§ A discussion onchallenges related to in-house manufacturing, featuring a brief overview of thevarious parameters that a drug / therapy developer may need to take intoconsideration while deciding whether to manufacture its products in-house oroutsource.
§ An analysis of the recent collaborations (signed since2013) focused on the contract manufacturing of biologics.
§ A detailed analysis of the various mergers and acquisitionsthat have taken place in this domain, highlighting the trend in the number ofcompanies acquired between 2013-2018, along with the geographical distributionof this activity.
§ An in-depth analysis of more than 490 grants that have beenawarded to research institutes engaged in next generation immune checkpointtherapy-related projects.
§ An analysis on the recent trends within biopharmaceuticalcontract manufacturing industry, highlighting various facility and capabilityexpansions.
§ A detailed capacity analysis, taking into consideration theindividual development and manufacturing capacities of various stakeholders.
§ A detailed capacity analysis, taking into consideration theindividual development and manufacturing capacities of various stakeholders.
§ A discussion on affiliated trends, key drivers, andchallenges, under a comprehensive SWOT framework.
§ A survey analysisfeaturing inputs solicited from various experts who are directly / indirectlyinvolved in providing CMO services to medical device developers.
§ A detailed market forecast, featuring analysis of thecurrent and projected future opportunity across key market segments (listedbelow)
§ Commonly Outsourced Business Operations
§ Active Pharmaceutical Ingredients (API)
§ Finished Dosage Formulations (FDF)
§ Types of Expression System
§ Mammalian
§ Microbial
§ Others
§ Company Size
§ Small
§ Mid-Sized
§ Large and Very Large
§ Scale of Operation
§ Preclinical
§ Clinical
§ Commercial
§ Key Geographical Region
§ North America
§ Europe
§ Asia-Pacific
§ Rest of the World
The report also features detailed transcripts ofdiscussions held with the following experts:
§ Astrid Brammer,Senior Manager Business Development, Richter-Helm Mathias Schmidt (ChiefExecutive Officer, ArmaGen)
§ Birgit Schwab, SeniorManager Strategic Marketing, Rentschler Biotechnologie
§ Christian Bailly,Director of CDMO, Pierre Fabre
§ Claire Otjes,Assistant Marketing Manager, Batavia Biosciences
§ David C Cunningham,Director Corporate Development, Goodwin Biotechnology
§ Dietmar Katinger,Chief Executive Officer, Polymun Scientific
§ Denis Angioletti,Chief Commercial Officer, Cerbios-Pharma
§ Jeffrey Hung, ChiefCommercial Officer, Vigene Biosciences
§ Kevin Daley, DirectorPharmaceuticals, Novasep
§ Mark Wright, SiteHead, Grangemouth, Piramal Healthcare
§ Nicolas Grandchamp,R&D Leader, GEG Tech
§ Raquel Fortunato,Chief Executive Officer, GenIbet Biopharmaceuticals
§ Sebastian Schuck,Head of Business Development, Wacker Biotech
§ Stephen Taylor,Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies
§ Tatjana Buchholz,Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager,PlasmidFactory
§ Tim Oldham, ChiefExecutive Officer, Cell Therapies
Keycompanies covered in the report
§ 3P Biopharmaceuticals
§ Abzena
§ Albany Molecular Research
§ BioVectra
§ BioXcellence (Boehringer Ingelheim)
§ Celonic
§ Charles River Laboratories
§ ChemPartner
§ Cobra Biologics
§ CordenPharma
§ Cytovance Biologics
§ GE Healthcare
§ Goodwin Biotechnology
§ Grand River Aseptic Manufacturing
§ IDT Biologika
§ KBI BioPharma
§ Kemwell Biopharma
§ LFB Biomanufacturing
§ Meridian Life Science
§ Patheon
§ Pfizer CentreOne
§ PX'Therapeutics
§ Samsung BioLogics
§ Sanofi, CEPiA
§ Thermo Fisher Scientific
§ Vetter Pharma International
Formore information please click on the following link:
BiopharmaContract Manufacturing Market (3rd Edition), 2019-2030
Other Recent Offerings
1. CellTherapy Manufacturing Market (3rd Edition), 2019-2030
2. AntibodyContract Manufacturing Market, 2020-2030
3. China Biopharmaceutical ContractManufacturing Market, 2020-2030
4. PeptideTherapeutics: Contract API Manufacturing Market, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing marketresearch companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
